62 related articles for article (PubMed ID: 10851496)
1. Prognostic significance of immunological evaluation in colorectal cancer.
Berghella AM; Pellegrini P; Del Beato T; Maccarone D; Adorno D; Casciani CU
Cancer Biother Radiopharm; 1996 Dec; 11(6):355-61. PubMed ID: 10851496
[TBL] [Abstract][Full Text] [Related]
2. Necessity of biotherapeutic treatments inducing TH1 cell functions in colorectal cancer.
Contasta I; Pellegrini P; Berghella AM; Del Beato T; Canossi A; Di Rocco M; Adorno D; Casciani CU
Cancer Biother Radiopharm; 1996 Dec; 11(6):373-83. PubMed ID: 10851498
[TBL] [Abstract][Full Text] [Related]
3. IL-10 and sIL-2R serum levels as possible peripheral blood prognostic markers in the passage from adenoma to colorectal cancer.
Berghella AM; Pellegrini P; Del Beato T; Adorno D; Casciani CU
Cancer Biother Radiopharm; 1997 Aug; 12(4):265-72. PubMed ID: 10851474
[TBL] [Abstract][Full Text] [Related]
4. The role of the soluble CD30 serum level in colorectal cancer: a possible marker for a patient subset which could benefit from IL-2 biotherapy.
Dle Beato T; Berghella AM; Pellegrini P; Domenico A; Casciani CU
Cancer Biother Radiopharm; 1997 Oct; 12(5):297-304. PubMed ID: 10851480
[TBL] [Abstract][Full Text] [Related]
5. The significance of an increase in soluble interleukin-2 receptor level in colorectal cancer and its biological regulating role in the physiological switching of the immune response cytokine network from TH1 to TH2 and back.
Berghella AM; Pellegrini P; Del Beato T; Marini M; Tomei E; Adorno D; Casciani CU
Cancer Immunol Immunother; 1998 Jan; 45(5):241-9. PubMed ID: 9439647
[TBL] [Abstract][Full Text] [Related]
6. Disease stage prognostic indices in the early clinical screening of colorectal cancer patients.
Pellegrini P; Berghella AM; Del Beato T; Maccarone D; Casciani CU; Adorno D
Cancer Biother Radiopharm; 1998 Apr; 13(2):89-98. PubMed ID: 10850345
[TBL] [Abstract][Full Text] [Related]
7. Significance of pre-treatment immunological parameters in colorectal cancer patients with unresectable metastases to the liver.
Zaloudik J; Lauerova L; Janakova L; Talac R; Simickova M; Nekulova M; Mikulikova I; Kovarik J; Sheard M
Hepatogastroenterology; 1999; 46(25):220-7. PubMed ID: 10228796
[TBL] [Abstract][Full Text] [Related]
8. Immunological directives for biotherapy improvement in the treatment of colorectal cancer.
Pellegrini P; Berghella AM; Del Beato T; Adorno D; Casciani CU
Cancer Biother Radiopharm; 1996 Apr; 11(2):113-8. PubMed ID: 10851527
[TBL] [Abstract][Full Text] [Related]
9. The effect of colorectal cancer upon host peripheral immune cell function.
Evans CF; Galustian C; Bodman-Smith M; Dalgleish AG; Kumar D
Colorectal Dis; 2010 Jun; 12(6):561-9. PubMed ID: 19250260
[TBL] [Abstract][Full Text] [Related]
10. The sCEA molecule suppressive role in NK and TH1 cell functions in colorectal cancer.
Pellegrini P; Berghella AM; Del Beato T; Maccarone D; Cencioni S; Adorno D; Casciani CU
Cancer Biother Radiopharm; 1997 Aug; 12(4):257-64. PubMed ID: 10851473
[TBL] [Abstract][Full Text] [Related]
11. Peripheral blood immunological parameters for use as markers of pre-invasive to invasive colorectal cancer.
Berghella AM; Contasta I; Pellegrini P; Del Beato T; Adorno D
Cancer Biother Radiopharm; 2002 Feb; 17(1):43-50. PubMed ID: 11915173
[TBL] [Abstract][Full Text] [Related]
12. High serum levels of soluble IL-2 receptor, cytokines, and C reactive protein correlate with impairment of T cell response in patients with advanced epithelial ovarian cancer.
Macciò A; Lai P; Santona MC; Pagliara L; Melis GB; Mantovani G
Gynecol Oncol; 1998 Jun; 69(3):248-52. PubMed ID: 9648596
[TBL] [Abstract][Full Text] [Related]
13. Circulating levels of soluble CD30 and other markers in colorectal cancer patients.
Iwagaki H; Hizuta A; Kohka H; Kobashi K; Nitta Y; Isozaki H; Takakura N; Tanaka N
J Med; 1999; 30(1-2):111-21. PubMed ID: 10515247
[TBL] [Abstract][Full Text] [Related]
14. [Relation of serum levels of the soluble cytoadhesion molecules sVCAM-1 and sICAM-1 to selected factors in the cytokine network in multiple myeloma].
Scudla V; Budíková M; Bacovský J; Opíchalová D; Farbiaková V
Cas Lek Cesk; 2000 Jul; 139(13):401-6. PubMed ID: 10971970
[TBL] [Abstract][Full Text] [Related]
15. Immunological implications of alterations in the c-Ki-ras and p53 genes in the stepwise progression of colorectal cancer: indications for the improvement of prognosis, biotherapy treatment and tumor biology understanding.
Contasta I; Pellegrini P; Berghella AM; Del Beato T ; Canossi A; Maccarone D; Papola F; Adorno D; Casciani CU
Cancer Biother Radiopharm; 1997 Dec; 12(6):385-93. PubMed ID: 10851492
[TBL] [Abstract][Full Text] [Related]
16. Correlation of clinical and immunological parameters of metastatic renal cell carcinoma patients undergoing therapy with interleukin 2, interferon-alpha and retinoic acid.
Elsässer-Beile U; Kölble N; Grussenmeyer T; Wetterauer U; Schultze-Seemann W
Anticancer Res; 1998; 18(3B):1883-90. PubMed ID: 9677439
[TBL] [Abstract][Full Text] [Related]
17. [Tuberculosis in compromised hosts].
Kekkaku; 2003 Nov; 78(11):717-22. PubMed ID: 14672050
[TBL] [Abstract][Full Text] [Related]
18. [Perioperative immunologic changes in colorectal cancer patients].
Neagu S; Lerescu L; Costea R; Tucureanu C; Caraş I; Gangură G; Pitica R; Sălăgeanu A
Chirurgia (Bucur); 2012; 107(1):59-65. PubMed ID: 22480118
[TBL] [Abstract][Full Text] [Related]
19. Mannoprotein-induced anti-U937 cell cytotoxicity in peripheral blood mononuclear cells from uninfected or HIV-infected subjects: role of interferon-gamma and tumor necrosis factor-alpha.
Gomez MJ; Torosantucci A; Quinti I; Testa U; Peschle C; Cassone A
Cell Immunol; 1993 Dec; 152(2):530-43. PubMed ID: 8258154
[TBL] [Abstract][Full Text] [Related]
20. Dendritic cell vaccination of patients with metastatic colorectal cancer.
Burgdorf SK
Dan Med Bull; 2010 Sep; 57(9):B4171. PubMed ID: 20816019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
